Scientists at Dartmouth Cancer Center have discovered that a common drug used to treat high blood pressure may also help fight cancer more effectively.
The study, published in The Journal for ImmunoTherapy of Cancer, shows that telmisartan can make a cancer drug called olaparib work better and potentially help more patients.
Olaparib is part of a group of drugs known as PARP inhibitors. These drugs target cancer by blocking its ability to repair damaged DNA.
Normally, cells can fix DNA damage and continue to grow. But when this repair system is blocked, cancer cells can no longer survive. This approach works best in cancers that already have weak repair systems, such as those with BRCA gene mutations.
The problem is that many cancers do not have these weaknesses. As a result, PARP inhibitors do not work well for all patients. Even when they do work, the effect may not last, as cancer cells can adapt and become resistant.
The new research shows that telmisartan may solve some of these problems. When combined with olaparib, telmisartan made cancer cells more sensitive to treatment. It increased the amount of DNA damage inside the cells and made it harder for them to recover.
The study also found that telmisartan helps activate the immune system. It increases signals that tell the body to attack cancer cells. At the same time, it reduces a protein called PD-L1, which cancer cells use to hide from immune attacks. This combination of effects makes the treatment more powerful.
What makes this discovery especially interesting is that telmisartan is already a well-known and widely used drug. It belongs to a group of medicines called angiotensin receptor blockers, which are commonly prescribed for high blood pressure. Among these drugs, only telmisartan showed this strong effect on cancer, suggesting it has unique properties.
Because telmisartan is already approved and considered safe, it may be easier to move this treatment into clinical use. The drug is taken orally and is generally well tolerated, which is important for patients undergoing cancer treatment.
Researchers have already begun testing this approach in real patients. One study is focusing on advanced prostate cancer, and another is looking at ovarian cancer that no longer responds to standard treatments. Early results are encouraging, with some patients showing strong responses.
From a scientific point of view, this study is important because it shows how combining different types of treatments can lead to better outcomes. It also highlights the value of reusing existing drugs in new ways, which can save time and reduce costs in drug development.
However, there are still limitations. Most of the evidence so far comes from preclinical research and early-stage trials. Larger studies are needed to confirm the benefits and understand any risks. It is also not yet clear which patients will benefit the most from this treatment.
In conclusion, this research opens a new path for improving cancer therapy. By combining a simple blood pressure drug with targeted cancer treatment, doctors may be able to help more patients and overcome some of the challenges of drug resistance. If future trials are successful, this approach could become an important part of cancer care.
If you care about blood pressure, please read studies about unhealthy habits that could increase high blood pressure risk, and eating eggs in a healthy diet may reduce risks of diabetes, high blood pressure.
For more information about blood pressure, please see recent studies that early time-restricted eating could help improve blood pressure, and results showing 12 foods that lower blood pressure.
Source: Dartmouth Cancer Center.
